Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

mogamulizumab 4denileukin diftitox 4Vorinostat 4Panobinostat 4zanolimumab 3cobomarsen 3Brentuximab Vedotin 3Bexarotene 3tenalisib 2selinexor 2marizomib 2hypericin 2Vitamin B 12 2Rituximab 2Folic Acid 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2tislelizumab 1tinostamustine 1sapacitabine 1romidepsin 1resminostat 1quisinostat 1ontuxizumab 1navitoclax 1forodesine 1fludarabine phosphate 1enzastaurin 1belinostat 1abexinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Cutaneous × ProMune × Clear all
NCT00043420 2009-02-12

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Pfizer

Phase 1/2 Completed
42 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡